Business
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
- Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after bot...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference\n\n\n .bwalignc { text-align: center; list-style-position: inside }\n.bwlistdisc { list-style-type: disc }\n.bwuline { text-decoration: underline }\n \n\n\n\n -\n \n\n Phase 1a data shows SAT-3247 was safe and well tolerated in 72 healthy volunteers after both single and repeated administration\n \n\n\n\n -\n \n\n Phase 1a data shows favorable pharmacokinetic (PK) profile of SAT-3247, reinforcing its potential as a first-of-its-kind oral therapy for Duchenne Muscular Dystrophy (DMD)\n \n\n\n\n -\n \n\n Enrollment and treatment are ongoing in the Phase 1b trial in adults with DMD\n \n\n\n\n\n\n\n\n Satellos Bioscience Inc.\n \n\n\n (TSX: MSCL, OTCQB: MSCLF)\n \n (“\n \n Satellos\n \n ” or the “\n \n Company\n \n ”), a biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, today announced initial Phase 1 data in an oral presentation at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas.\n \n\n “We are very pleased by these early clinical data reinforcing the translation of SAT-3247’s preclinical pharmacokinetic and safety profile,” said Frank Gleeson, Satellos Co-Founder and CEO. “We believe these clinical results support the potential for SAT-3247 to have a desirable therapeutic profile as a first-of-its-kind oral therapy for people living with DMD.”\n \n\n SAT-3247 is designed to address progressive muscle loss in DMD patients by aiming to restore regeneration in response to damage. A Phase 1 trial with SAT-3247 is being conducted in healthy volunteers and adults with DMD (Phase 1a and Phase 1b, respectively).\n \n\n In the Phase 1a, designed to assess the safety and tolerability of SAT-3247, 72 healthy volunteers were randomized across five single ascending dose (SAD) cohorts (including one food effect cohort) with single oral doses of up to 400 mg, and four MAD cohorts with daily oral doses up to 240 mg/day for 7 days. As of a Feb. 20, 2025, data cut-off:\n \n\n\n Phase 1a data showed that SAT-3247 was safe and well tolerated across all healthy volunteer cohorts. At predicted human efficacious dose levels,...